141 related articles for article (PubMed ID: 11021743)
41. Antitumor efficacy of taxane liposomes on a human ovarian tumor xenograft in nude athymic mice.
Sharma A; Straubinger RM; Ojima I; Bernacki RJ
J Pharm Sci; 1995 Dec; 84(12):1400-4. PubMed ID: 8748320
[TBL] [Abstract][Full Text] [Related]
42. In vivo evaluation of ixabepilone (BMS247550), a novel epothilone B derivative, against pediatric cancer models.
Peterson JK; Tucker C; Favours E; Cheshire PJ; Creech J; Billups CA; Smykla R; Lee FY; Houghton PJ
Clin Cancer Res; 2005 Oct; 11(19 Pt 1):6950-8. PubMed ID: 16203787
[TBL] [Abstract][Full Text] [Related]
43. Pattern of antitumor activity of a novel camptothecin, ST1481, in a large panel of human tumor xenografts.
Pratesi G; De Cesare M; Carenini N; Perego P; Righetti SC; Cucco C; Merlini L; Pisano C; Penco S; Carminati P; Vesci L; Zunino F
Clin Cancer Res; 2002 Dec; 8(12):3904-9. PubMed ID: 12473606
[TBL] [Abstract][Full Text] [Related]
44. CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.
Ruggeri B; Singh J; Gingrich D; Angeles T; Albom M; Yang S; Chang H; Robinson C; Hunter K; Dobrzanski P; Jones-Bolin S; Pritchard S; Aimone L; Klein-Szanto A; Herbert JM; Bono F; Schaeffer P; Casellas P; Bourie B; Pili R; Isaacs J; Ator M; Hudkins R; Vaught J; Mallamo J; Dionne C
Cancer Res; 2003 Sep; 63(18):5978-91. PubMed ID: 14522925
[TBL] [Abstract][Full Text] [Related]
45. Therapeutic advantage from combining paclitaxel with the hypoxia-selective cytotoxin NLCQ-1 in murine tumor- or human xenograft-bearing mice.
Papadopoulou MV; Ji M; Ji X; Bloomer WD; Hollingshead MG
Cancer Chemother Pharmacol; 2002 Dec; 50(6):501-8. PubMed ID: 12451478
[TBL] [Abstract][Full Text] [Related]
46. Correlation of pharmacokinetics with the antitumor activity of Cetuximab in nude mice bearing the GEO human colon carcinoma xenograft.
Luo FR; Yang Z; Dong H; Camuso A; McGlinchey K; Fager K; Flefleh C; Kan D; Inigo I; Castaneda S; Rose WC; Kramer RA; Wild R; Lee FY
Cancer Chemother Pharmacol; 2005 Nov; 56(5):455-64. PubMed ID: 15947929
[TBL] [Abstract][Full Text] [Related]
47. Antitumor activity of a novel podophyllotoxin derivative (TOP-53) against lung cancer and lung metastatic cancer.
Utsugi T; Shibata J; Sugimoto Y; Aoyagi K; Wierzba K; Kobunai T; Terada T; Oh-hara T; Tsuruo T; Yamada Y
Cancer Res; 1996 Jun; 56(12):2809-14. PubMed ID: 8665518
[TBL] [Abstract][Full Text] [Related]
48. Identification of human uroplakin II promoter and its use in the construction of CG8840, a urothelium-specific adenovirus variant that eliminates established bladder tumors in combination with docetaxel.
Zhang J; Ramesh N; Chen Y; Li Y; Dilley J; Working P; Yu DC
Cancer Res; 2002 Jul; 62(13):3743-50. PubMed ID: 12097284
[TBL] [Abstract][Full Text] [Related]
49. Synthesis and biological evaluation of paclitaxel-C225 conjugate as a model for targeted drug delivery.
Safavy A; Bonner JA; Waksal HW; Buchsbaum DJ; Gillespie GY; Khazaeli MB; Arani R; Chen DT; Carpenter M; Raisch KP
Bioconjug Chem; 2003; 14(2):302-10. PubMed ID: 12643740
[TBL] [Abstract][Full Text] [Related]
50. Antitumor activity and biochemical effects of aphidicolin glycinate (NSC 303812) alone and in combination with cisplatin in vivo.
O'Dwyer PJ; Moyer JD; Suffness M; Harrison SD; Cysyk R; Hamilton TC; Plowman J
Cancer Res; 1994 Feb; 54(3):724-9. PubMed ID: 8306334
[TBL] [Abstract][Full Text] [Related]
51. Preclinical evaluation of docetaxel (Taxotere).
Lavelle F; Bissery MC; Combeau C; Riou JF; Vrignaud P; André S
Semin Oncol; 1995 Apr; 22(2 Suppl 4):3-16. PubMed ID: 7740328
[TBL] [Abstract][Full Text] [Related]
52. Comparison of paclitaxel and docetaxel activity on human ovarian carcinoma xenografts.
Nicoletti MI; Lucchini V; D'Incalci M; Giavazzi R
Eur J Cancer; 1994; 30A(5):691-6. PubMed ID: 7915909
[TBL] [Abstract][Full Text] [Related]
53. Pharmacokinetic profile of the microtubule stabilizer patupilone in tumor-bearing rodents and comparison of anti-cancer activity with other MTS in vitro and in vivo.
O'Reilly T; Wartmann M; Brueggen J; Allegrini PR; Floersheimer A; Maira M; McSheehy PM
Cancer Chemother Pharmacol; 2008 Nov; 62(6):1045-54. PubMed ID: 18301895
[TBL] [Abstract][Full Text] [Related]
54. Therapeutic cure against human tumor xenografts in nude mice by a microtubule stabilization agent, fludelone, via parenteral or oral route.
Chou TC; Dong H; Zhang X; Tong WP; Danishefsky SJ
Cancer Res; 2005 Oct; 65(20):9445-54. PubMed ID: 16230408
[TBL] [Abstract][Full Text] [Related]
55. Novel biocompatible intraperitoneal drug delivery system increases tolerability and therapeutic efficacy of paclitaxel in a human ovarian cancer xenograft model.
Vassileva V; Grant J; De Souza R; Allen C; Piquette-Miller M
Cancer Chemother Pharmacol; 2007 Nov; 60(6):907-14. PubMed ID: 17375303
[TBL] [Abstract][Full Text] [Related]
56. Disposition of conjugate-bound and free doxorubicin in tumor-bearing mice following administration of a BR96-doxorubicin immunoconjugate (BMS 182248).
Mosure KW; Henderson AJ; Klunk LJ; Knipe JO
Cancer Chemother Pharmacol; 1997; 40(3):251-8. PubMed ID: 9219510
[TBL] [Abstract][Full Text] [Related]
57. Preclinical antitumor activity of BMS-214662, a highly apoptotic and novel farnesyltransferase inhibitor.
Rose WC; Lee FY; Fairchild CR; Lynch M; Monticello T; Kramer RA; Manne V
Cancer Res; 2001 Oct; 61(20):7507-17. PubMed ID: 11606387
[TBL] [Abstract][Full Text] [Related]
58. Antitumor activity of taxotere (RP 56976, NSC 628503), a new taxol analog, in experimental ovarian cancer.
Boven E; Venema-Gaberscek E; Erkelens CA; Bissery MC; Pinedo HM
Ann Oncol; 1993 Apr; 4(4):321-4. PubMed ID: 8100146
[TBL] [Abstract][Full Text] [Related]
59. IDN5109, a taxane with oral bioavailability and potent antitumor activity.
Nicoletti MI; Colombo T; Rossi C; Monardo C; Stura S; Zucchetti M; Riva A; Morazzoni P; Donati MB; Bombardelli E; D'Incalci M; Giavazzi R
Cancer Res; 2000 Feb; 60(4):842-6. PubMed ID: 10706091
[TBL] [Abstract][Full Text] [Related]
60. Complete regression of xenografted human carcinomas by a paclitaxel-carboxymethyl dextran conjugate (AZ10992).
Sugahara S; Kajiki M; Kuriyama H; Kobayashi TR
J Control Release; 2007 Jan; 117(1):40-50. PubMed ID: 17126446
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]